Collaborative Prescribing Agreement Naltrexone



-April 8, 2021-

Collaborative Prescribing Agreement Naltrexone

Mike Burroughs

External barriers generally differ from the barriers to access and acceptance described above in Table 4. The external barriers identified focus on issues such as the lack of resources in the Community to support the coordination of care or provide the packaging services that the patient needs to adequately treat his chronic diseases related to EDIs. For example, a pharmacist mentioned the desire to involve patients with a convalescent coach in the community to help the patient and improve the likelihood that the patient will return for subsequent naltrexone injections. The remaining external barriers focus on evaluating providers and patients through their community pharmacy and available services. For example, community residents may believe that the local community pharmacy primarily fills prescriptions in the retail sector and does not provide clinical services, including naltrexone injections for people with ADUs. In general health practice, physicians can practice telemedicine to facilitate remote treatment. When pharmacists and physicians work together to conduct a telemedicine visit, as we interviewed by pharmacists, it offers a new location (i.e. a community pharmacy) for the provider-patient visit. The procedure then facilitates the injection of naltrexone by the pharmacist. The absence of a parallel provision of telemedicine in pharmacy practice laws, without clarifying binding statements, creates uncertainty about the legality of pharmacists` participation in interactions between physicians or patients through telemedicine consultations. In order to create a clearly defined power for pharmacists to do telemedicine, the Pharmacy Inspection Service could amend its regulations to allow such a practice.

Such a regulatory change, combined with a strategy of communicating to its licensees about change, has the potential to facilitate pharmacist service around the treatment of naltrexone for patients with OUD and to expand access to MOUD treatment. Information from the interviews was verified to identify specific points and topics related to the naltrexone injection process in each community pharmacy. The authors separately analyzed the content of the interviews, then met to reach a consensus on their interpretation of the identified content and discuss and negotiate the classification and designation of processes and thematic areas related to the naltrexone injection process derived from the interview data. Naltrexone binds to endorphin receptors in the body, and blocks the effects and sensations of alcohol. Naltrexone reduces alcohol cravings and the amount of alcohol consumed.


SHARE THE ARTICLE
click below to share with friends and social networks
Facebook Twitter Tumblr Stumbleupon Reddit Email







DISCUSS THE ARTICLE
Leave a comment and participate in the discussion.
Social links powered by Ecreative Internet Marketing